In an effort to potentiate CD8+ T cells, avasimibe, an ACAT-1 inhibitor, was combined with nanoliposomes containing paclitaxel and the immunoadjuvant α-GalCer for chemoimmunotherapy of a melanoma model [60]. Here, CD8A is linked to melanoma.